Compare Quest Diagnostics Inc (DGX) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Gartner Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Gartner Inc trades at $197.36 (market cap $12.34B). The key difference: Quest Diagnostics Inc is far larger — about 2.1× Gartner Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Gartner Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Gartner Inc for 64 Days on average.
| DGX | IT | |
|---|---|---|
Market Cap | $25.48B | $12.34B |
Volume | 941,866 | 919,809 |
Sector | Health | Technology |
52-Week High | $247.45 | $258.17 |
52-Week Low | $173.49 | $125.68 |
Typical Hold Time | 56 Days | 64 Days |
Enterprise Value | $31.23B | $14.08B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
Gartner (IT) trades at $185.77, up 0.46% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 69.63% gross margin and 12% net income margin, though 2025 net income declined to $729 million. Recent news highlights AI advisory demand and a shareholder investigation, while analyst consensus is mixed with a $174.63 price target below the current price.
Outlook remains supported by high ROE and consulting industry growth, but risks include the shareholder fiduciary probe and volatile cash flows. The stock faces resistance near $188, with valuation metrics like P/E of 17.57 appearing reasonable if earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
